Abstract:Introduction: Peripheral T-cell lymphoma (PTCL) constitute a heterogenous group of non-Hodgkin lymphomas, which is distinguished by their aggressive courses and poor clinical outcomes. Multiple researches have indicated that the JAK/STAT pathway acts as an important role in the mechanism of TCL pathogenesis. Preliminary results from related clinical studies showed that JAK inhibitors have a high remission rate and durable response in PTCL patients. AZD4205 is a potent JAK1-selective inhibitor currently evaluated in phase II clinical studies in PTCLs, which could reduce the side effects caused by JAK2 blockade by selectively targeting JAK1. Therefore, the aim of this study is to explore the efficacy and appropriate combination regimen of the novel JAK1 inhibitor AZD4205 in PTCL and to decipher the underlying anti-tumor mechanism. Methods: We analyzed the expression of JAK/STAT pathway in PTCL tissues via bioinformatics analysis and IHC. In vitro cell viability was assessed by using Cell Titer-Glo Luminescent assay. Induction of cell apoptosis was measured by flow cytometry. Western blot was utilized to identify the influence of AZD4205 on the intracellular relevant signaling pathways. The effects of AZD4205 on the transcriptome of PTCL cells were analyzed via transcriptome sequencing technology. High-throughput compounds screening was applied to explore potential combination therapeutic targets of AZD4205. Tumor-bearing mouse models were established to validate the efficacy and safety of AZD4205 and the combination regimen. Results: High expression of phosphorylated JAK1 in PTCL tissues are potential poor prognostic factors. The JAK1 inhibitor AZD4205 inhibited the proliferation of PTCL cells and down-regulated the activation of JAK/STAT signaling pathway. In addition, AZD4205 induced apoptosis in PTCL cells, and showed anti-tumor effects in vivo. However, AZD4205 also induced adverse effects of hepatic impairment and dyslipidemia in vivo. Transcriptome sequencing analysis revealed that AZD4205 treatment upregulated the expression of mTOR pathway-related genes. Moreover, high-throughput screening assay showed that the mTOR inhibitor everolimus significantly enhanced the inhibitory efficacy of AZD4205. We further confirmed that AZD4205 combined with the mTOR inhibitor everolimus exerted synergistic anti-PTCL efficacy both in vitro and in vivo, and the combination regimen significantly reduced AZD4205-induced adverse effects. The RNA-seq results suggested that the combination treatment affected the cholesterol homeostasis pathway and a further validation of the combined anti-PTCL effect of mevastatin and AZD4205 was confirmed in mouse models. Keywords: Aggressive T-cell non-Hodgkin lymphoma, Combination Therapies, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract.

The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B-Cell Lymphoma

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

Small molecule inhibitor combination treatment effectively represses global B-cell signaling in diffuse large B-cell lymphoma

β-Sitosterol Inhibits Tumor Growth and Amplifies Rituximab Sensitivity through Acid Sphingomyelinase/Ceramide Signaling in Diffuse Large B-Cell Lymphoma

Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia

The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma

Combination of Enzastaurin and Ibrutinib Synergistically Induces Anti-Tumor Effects in Diffuse Large B Cell Lymphoma

Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells

The Mtor Kinase Inhibitor Everolimus Synergistically Enhances the Anti-Tumor Effect of the Bruton's Tyrosine Kinase (BTK) Inhibitor PLS-123 on Mantle Cell Lymphoma

Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis

Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors

Down-Regulation of SREBP via PI3K/AKT/mTOR Pathway Inhibits the Proliferation and Invasion of Non-Small-Cell Lung Cancer Cells

Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma

SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway

Prediction and Optimization of the Therapeutic Effect of Mtor Inhibitors in Aggressive B-Cell Lymphomas

Leveraging altered lipid metabolism in treating B cell malignancies

Resveratrol induces autophagy impeding BAFF-stimulated B-cell proliferation and survival by inhibiting the Akt/mTOR pathway

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma

Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL

Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in post-transplant lymphoproliferative disorder